Evaluating the efficacy of eicosapentaenoic acid in patients with acute respiratory distress syndrome

Evaluating the efficacy of eicosapentaenoic acid in patients with acute respiratory distress syndrome: A Randomized Controlled Trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170608034390N18

Enrollment

Registered

2025-05-25

Start date

2025-06-10

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome. Acute respiratory distress syndrome

Interventions

Intervention 1: Intervention group: The intervention group will receive 6 grams of eicosapentaenoic acid daily for 1 week as an add-on treatment. Intervention 2: Control group: In this group, 6 grams

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Mild to moderate acute respiratory distress syndrome (ARDS) with PaO2/FiO2 between 100 and 300 mmHg Adult Patients (older than 18 years) Receiving mechanical ventilation Bilateral pulmonary infiltration

Exclusion criteria

Exclusion criteria: Hypersensitivity to any component of the product Pregnancy Platelet count below 50,000/µl Patients with increased risk of bleeding Hepatic insufficiency

Design outcomes

Primary

Measure	Time frame
Ratio of arterial partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (FiO2). Timepoint: Before intervention and 4 and 7 days after intervention. Method of measurement: Arterial Blood Gas (ABG) test.	—

Secondary

Measure	Time frame
Duration of mechanical ventilation (days). Timepoint: Before intervention and at the time of extubation. Method of measurement: Observation.;ICU length of stay (days). Timepoint: Before intervention and at the end of an ICU admission. Method of measurement: Observation.;Organ Failure Assessment. Timepoint: Before intervention and 4 and 7 days after intervention. Method of measurement: Evaluation of various parameters such as clinical and blood serum factors.;Changes in oxygenation and breathing pattern. Timepoint: Before intervention and 4 and 7 days after intervention. Method of measurement: Ventilator-derived parameters.	—

Measure

Time frame

Duration of mechanical ventilation (days). Timepoint: Before intervention and at the time of extubation. Method of measurement: Observation.;ICU length of stay (days). Timepoint: Before intervention and at the end of an ICU admission. Method of measurement: Observation.;Organ Failure Assessment. Timepoint: Before intervention and 4 and 7 days after intervention. Method of measurement: Evaluation of various parameters such as clinical and blood serum factors.;Changes in oxygenation and breathing pattern. Timepoint: Before intervention and 4 and 7 days after intervention. Method of measurement: Ventilator-derived parameters.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Esmaily

Shahid Beheshti University of Medical Sciences

Esmaily_hadi@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026